Hamad Bin Khalifa University to Host Conference on AI Ethics
25.8.2025 12:30:00 CEST | Business Wire | Press Release
Hamad Bin Khalifa University (HBKU) will be hosting a landmark conference in Doha on AI Ethics: The Convergence of Technology and Diverse Moral Traditions from September 28–29, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250825570906/en/
Hamad Bin Khalifa University to Host Conference on AI Ethics (Infographic: AETOSWire)
This milestone event is set to be an important convergence point for leading academics, policy makers, tech industry experts, ethicists, and others, to explore how AI is transforming societies and how globally diverse value systems should frame its responsible development and deployment. Socially-disruptive technologies are increasingly affecting our daily lives and, with technological innovation outpacing regulatory frameworks worldwide, meaningful international action is needed to ethically shape rules and guidelines to protect cultural and human norms.
The conference will highlight the need for cross-sector collaboration to ensure ethical AI development and standards across six thematic areas: healthcare; urban design; security; education; finance; and the future of the workplace.
The conference seeks to advance cohesive international standards that mitigate the risk of institutional exposure to possible liabilities and protect individuals and communities that may be adversely affected by these extremely rapid developments. The imperative to consider collective responsibility and foster cross-disciplinary partnerships has never been more apparent. The conference offers a frame to conscientiously and collaboratively shape solutions guided by the diverse values and needs of our global society.
VENUE: Qatar National Convention Center (QNCC), Doha, Qatar.
MISSION: To critically examine the ethical implications of AI and promote a cross-cultural, multidisciplinary dialogue that ensures AI advances aligned with global moral frameworks.
FEATURED SPEAKERS: Ibtihal Aboussad, formerly Microsoft; Amr Awadallah, Vectara; Daniel González-Bootello, Smart City Cluster; Mark Coeckelbergh, University of Vienna; Yali Cong, Peking University; Munther Dahleh, MIT; Corey Gray, Smart Cities Council; David Gunkel, Northern Illinois University; Jeroen van den Hoven, Delft Design for Values Institute; Nancy Jecker, University of Washington; David Leslie, The Alan Turing Institute; Yuan Luo, Northwestern University; Beth McGinty, Weill Cornell Medical College.
Media Access: Credentialed journalists will have access to keynote sessions, expert panels, and select one-on-one interview opportunities with featured speakers. A list of speakers and detailed agenda can be foundhere.
Disclaimer: Guest participation in the conference is evolving and may therefore be subject to updates.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250825570906/en/
Contacts
For media inquiries or to request accreditation, please contact:
Ms. Taiba Saoud Al-Rodaini
media@hbku.edu.qa
Tel: +974 44540934
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom